NICE Approves New Lung Cancer Treatment
Continuous researches and studies are being conducted to extend life of lung cancer patients by innovating new methods and techniques. A new research has been conducted by NICE. The National Institute for Health and Care Excellence (NICE) has recommended in draft guidance that pembrolizumab combined with pemetrexed and platinum chemotherapy is an option for untreated advanced lung cancer patients. Pembrolizumab is an immunotherapy drug also called as Keytruda and is used by thousands of lung cancer patients. It is administrated every three weeks by intravenous infusion. In the study, Pembrolizumab combined with pemetrexed and platinum chemotherapy gave patients four additional months without their cancer progressing as compared to the standard treatment of pemetrexed with platinum chemotherapy. This makes pembrolizumab the first immunotherapy to be made available to NHS patients in England used in combination with chemotherapy for treatment of advanced non-small cell lung cancer.
Post to Tumblr